Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study.
The effectiveness of chemoimmunotherapy was evaluated in 45 previously untreated stage III ovarian cancer patients. Response rate, progression-free interval, and survival were considerably better than in a similar group of 63 patients treated with a single alkylating agent alone.
D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008558:Melphalan / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D011425:Propionibacterium acnes / Q000276:immunology*; D012075:Remission, Spontaneous; D013997:Time Factors
D008558:Melphalan